During the last session, PAVmed Inc. (NASDAQ:PAVM)’s traded shares were 2.19 million, with the beta value of the company hitting 0.22. At the end of the trading day, the stock’s price was $1.08, reflecting an intraday loss of -4.42% or -$0.05. The 52-week high for the PAVM share is $9.70, that puts it down -798.15 from that peak though still a striking 12.96% gain since the share price plummeted to a 52-week low of $0.94. The company’s market capitalization is $103.81M, and the average trade volume was 1.76 million shares over the past three months.
PAVmed Inc. (PAVM) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. PAVM has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.2.
PAVmed Inc. (NASDAQ:PAVM) trade information
PAVmed Inc. (PAVM) registered a -4.42% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.42% in intraday trading to $1.08 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -23.40%, and it has moved by 5.88% in 30 days. Based on these gigs, the overall price performance for the year is -72.86%.
The consensus price target of analysts on Wall Street is $6.38, which implies an increase of 83.07% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $9.50 respectively. As a result, PAVM is trading at a discount of -779.63% off the target high and -270.37% off the low.
PAVmed Inc. (PAVM) estimates and forecasts
Statistics show that PAVmed Inc. has underperformed its competitors in share price, compared to the industry in which it operates. PAVmed Inc. (PAVM) shares have gone down -78.18% during the last six months, with a year-to-date growth rate less than the industry average at -106.98% against 3.50. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -53.80% this quarter and then drop -50.00% in the quarter after that. In the rating firms’ projections, revenue will increase 1,040.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $350k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $820k by the end of Jun 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -8.40%. While earnings are projected to return 10.40% in 2022.
PAVmed Inc. is due to release its next quarterly earnings between August 10 and August 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
PAVmed Inc. (NASDAQ:PAVM)’s Major holders
PAVmed Inc. insiders own 10.33% of total outstanding shares while institutional holders control 30.92%, with the float percentage being 34.49%. Blackrock Inc. is the largest shareholder of the company, while 138 institutions own stock in it. As of Dec 30, 2021, the company held over 4.79 million shares (or 5.44% of all shares), a total value of $11.77 million in shares.
The next largest institutional holding, with 4.1 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.66% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $10.09 million.
Also, the Mutual Funds coming in first place with the largest holdings of PAVmed Inc. (PAVM) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 2.27 million shares. This amounts to just over 2.58 percent of the company’s overall shares, with a $5.58 million market value. The same data shows that the other fund manager holds slightly less at 1.66 million, or about 1.89% of the stock, which is worth about $2.86 million.